Recent advances in Pharmacokinetic modeling

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 3, 2007, Pages 135-143

  Ahmad, Alaa M ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Compartmental modeling; Mechanistic models; Pharmacokinetics; Population methodologies

Indexed keywords

ADENOSINE A1 RECEPTOR AGONIST; AMPRENAVIR; ANTIGLAUCOMA AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BENSERAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUNAZOSIN; CIMETIDINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME P450 3A; ERYTHROMYCIN; EZETIMIBE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPOCHOLESTEROLEMIC AGENT; IDARUBICIN; IDARUBICINOL; ITRACONAZOLE; LEVODOPA; MIDAZOLAM; OPIATE DERIVATIVE; PHENOBARBITAL; RANITIDINE; RITONAVIR; RUTOSIDE; TRIFLURIDINE; UNINDEXED DRUG; URACIL DERIVATIVE; ZIDOVUDINE;

ANALYTIC METHOD; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG TISSUE LEVEL; DRUG TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; NONHUMAN; PLASMA PROTEIN BINDING; REVIEW; STATISTICAL ANALYSIS;

ANIMALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACOKINETICS; TISSUE DISTRIBUTION;

EID: 34248330076     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.540     Document Type: Review

References (50)

1. Gibaldi M, Perrier D. Pharmacokinetics, 2nd edn. Dekker: New York, 1982.
2. Sheiner LB, Rosenberg B, Melmon VV. Modeling of individual pharmacokinetics for computer-aided drug dosing. Comput Biomed Res 1972; 5: 441-459.
3. Beal SL, Sheiner LB. Estimating population kinetics. CRC Crit Rev Bioeng 1982; 8: 195-222.
4. Rowland M, Sheiner L, Steimer JL. Variability in Drug Therapy: Description, Estimation and Control. Raven Press: New York; 1985.
5. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol 1992; 32: 185-209.
6. Samara E, Granneman R. Role of population pharmacokinetics in drug development. Clin Pharmcokinet 1997; 32: 294-312.
7. Kwon Y. Handbook of Essential Pharmacokinetics, Pharmacodynamics, and Drug Metabolism for Industrial Scientists. Kluwer Academic Publishers: Norwell, 2001.
8. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythromycin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004; 44: 991-1002.
9. Suttle AB, Pollack GM, Brouwer KLR. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharm Res 1992; 9: 350-355.
10. Wright JD, MA T, Chu CK, Boudinot FD. Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-flouro-5-methyl-β-L-arabinofuranosyl)uracil (L-FMAU) in rats. Biopharm Drug Dispos 1996; 17: 197-207.
11. International Neoral Renal Transplantation Study Group. Cyclosporine micro emulsion (Neoral) absorption profiling and sparse-sample predictors during the first three months after renal transplantation. Am J Transplant 2002; 2: 148-156.
12. Debord J, Risco E, Harel M, et al. Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 2001; 40: 375-382.
13. Leger F, Debord J, Le Meur Y, et al. Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants. Clin Pharmacokinet 2002; 41: 71-80.
14. Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC (0-12) monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol 2003; 58: 813-820.
15. Rousseau A, Monchaud C, Debord J, et al. Bayesian forecasting of oral cyclosporin pharmacokinetics in stable lung transplant recipients with and without cystic fibrosis. Ther Drug Monit 2003; 25: 28-35.
16. Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporine using NONMEM. Ther Drug Monit 2004; 26: 23-30.
17. Gallo GM, Etse JT, Doshi KJ, Boudinot FD, Chu CK. Hybrid pharmacokinetic models to describe anti-HIV nucleoside brain disposition following parent and pro-drug administration in mice. Pharm Res 1991; 8: 247-253.
18. Gallo JM, Vicini P, Orlansky A, et al. Pharmacokinetic model-predicted anti-cancer drug concentrations in human tumors. Clin Cancer Res 2004; 10: 8048-8058.
19. Huang CS-H, Boudinot FD, Feldman S. Maternal-fetal pharmacokinetics of Zidovudine in rats. J Pharm Sci 1996; 85: 965-970.
20. Tunblad K, Hammarlund-Udenaes M, Jonsson EN. An integrated model for the analysis of pharmacokinetic data from microdialysis experiments. Pharm Res 2004; 21: 1698-1707.
21. 1 receptor agonists. J Pharmacol Exp Ther 2004; 311: 1138-1146.
22. Ummenhofer WC, Arends RH, Shen DD, Bernards CM. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fentanyl, alfentanil and sulfentanil. Anesthesiology 2000; 92: 739-753.
23. Sakanaka K, Kawazu K, Tomonari M, et al. Ocular pharmacokinetic/ pharmacodynamic modeling for bunazosin after instillation into rabbits. Pharm Res 2004; 21: 770-776.
24. Ranta V-P, Laavola M, Toropainen E, Vellonen K-S, Talvitie A, Urtii A. Ocular pharmacokinetic modeling using corneal sorption and desorption rates from in vitro permeation experiments with cultured corneal epithelial cells. Pharm Res 2003; 20: 1409-1416.
25. Ezzet F, Krishna G, Wexler DB, et al. A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 2001; 23: 871-885.
26. Yamano K, Yamamoto K, Katashima M, et al. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution and metabolism data. Drug Metab Dispos 2001; 29(4), part 1, 443-452.
27. Grange S, Holford NHG, Guentert TW. A pharmacokinetic model to predict the PK interaction of L-dopa and benserazide in rats. Pharm Res 2001; 18: 1174-1184.
28. Minotti G, Parlani M, Salvatorelli E, et al. Impairment of myocardial contractility by anticancer anthracylines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. Br J Pharmacol 2001; 134: 1271-1278.
29. Weiss M, Kang W. P-glycoprotein inhibitors enhance saturable uptake of idarubicin in rat heart: pharmacokinetic/pharmacodynamic modeling. J Pharmacol Exp Ther 2002; 300: 688-694.
30. Kang W, Weiss M. Modeling the metabolism of idarubicin to idarubicinol in rat heart: effect of rutin and phenobarbital. J Pharmacol Exp Ther 2003; 31: 462-468.
31. Emura T, Nakagawa F, Fujioka A, et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 2004; 13: 249-255.
32. Fukushima M, Suzuki N, Emura T, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 2000; 59: 1227-1236.
33. Tsuchiya T, Kuwata K, Nagayama S, et al. Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor. Drug Metab Pharmacokin 2004; 19: 206-215.
34. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother 2002; 46(3): 746-754.
35. Ward ES, Pollack GM, Brouwer KLR. Probenecid-associated alterations in valproate glucuronide hepatobiliary disposition: mechanistic assessment using mathematical modeling. J Pharmacol Exp Ther 2001; 297: 141-147.
36. Svensson USH, Maki-Jouppila M, Hoffmann K-J, Ashton M. Characterization of the human liver in vitro metabolic pattern of artemisinin and auto-induction in the rat by the use of non-linear mixed effects modeling. Biopharm Drug Dispos 2003; 24: 71-85.
37. Hassan M, Svensson USH, Ljungman P, et al. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol 1999; 48: 669-677.
38. Kerbusch T, Mathot RAA, Keizer HJ, et al. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos 2001; 29: 967-975.
39. Lotsch J, Skarke C, Schmidt H, et al. Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers. Clin Pharmacol Ther 2002; 72: 151-162.
40. Xie R, Mathijssen HJ, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol 2002; 20: 3293-3301.
41. Sun L, Lau CE. Simultaneous pharmacokinetic modeling of cocaine and its metabolites, norcocaine and benzoylecgonine, after intravenous and oral administration in rats. Drug Metab Dispos 2001; 29: 1183-1189.
42. Ni L, Boudinot FD. Non-linear renal and biliary clearances of antiviral polyoxometalates in rats. Eur J Drug Metab Pharmacokinet 1995; 20: 209-217.
43. Hansen RJ, Balthasar JP. Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharm Sci 2003; 92: 1206-1215.
44. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994; 56: 248-252.
45. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-532.
46. Fossler MJ, Ebling WF, Ma S, et al. Integrated pharmacokinetic/ pharmacodynamic model of XV459, a potent and specific GP2b/3a inhibitor, in healthy male volunteers. J Clin Pharmacol 2002; 42: 1326-1334.
47. Mager DE, Mascelli MA, Kleiman NS, et al. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 2003; 307: 969-976.
48. Levy G, Mager DE, Cheung WK, Jusko WJ. Comparative pharmacokinetics of coumarin anticoagulants L: physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci 2003; 92: 985-994.
49. Mager DE, Neuteboom B, Efthymiopoulos C, et al. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-β1a in monkeys. J Pharmacol Exp Ther 2003; 306: 262-270.
50. Wang B, Ludden TM, Cheung EN, et al. Population pharmacokinetic pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. J Pharmacokinet Pharmacodyn 2001; 28: 321-342.